Drug profile · INN
rifaximin
XIFAXAN
rifaximin (XIFAXAN) is a bacterial dna-directed rna polymerase inhibitor. Associated with Norgine Pty.. Route of administration: oral. Current US regulatory status: approved.
Drug details — rifaximin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 13
- Data quality
- 0.84
Quick answer
rifaximin (XIFAXAN) is a bacterial dna-directed rna polymerase inhibitor. Associated with Norgine Pty.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA-directed RNA polymerase inhibitor
Primary target: Bacterial DNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is rifaximin?
rifaximin (XIFAXAN) is a bacterial dna-directed rna polymerase inhibitor. Associated with Norgine Pty.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rifaximin?
XIFAXAN is a marketed brand name for rifaximin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rifaximin?
rifaximin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.